Clinical trial
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head…
NCT00392665 · Massachusetts General Hospital, Other · Terminated
Key facts
| NCT number | NCT00392665 |
|---|---|
| Title | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck |
| Official title | Randomized Study of Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Emory University University of North Carolina, Chapel Hill Genentech, Inc. Industry OSI Pharmaceuticals |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Intervention type | Drug |
| Interventions | Bevacizumab, erlotinib, Sulindac |
| Enrollment | 36 |
| Start date | Oct 1, 2006 |
| Primary completion | Aug 1, 2012 |
| Completion | Dec 1, 2013 |
| First posted | Oct 26, 2006 |
| Last update posted | Apr 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: